Abstract IA01: Potential applications of genomics in patients with metastatic breast cancer

Genomic studies have shown that breast cancer includes large number of genomic segments. From this observation has arisen the concept that sequencing could be used to select breast cancer patients for new therapies. There are at least six applications of genomic tests to individualize therapy in breast cancer. In the present document and presentation, we will only focus on metastatic breast cancers.First, genomic tests can be used to identify oncogenic drivers at the individual level. There are seven genomic alterations that are currently the focus on genomic-driven drug development. This includes AKT1 mutations, ERBB2 mutations, PIK3CA mutations, FGFR1 amplification, CCND1 amplification, BRCA1/2 mutations and PTEN mutations or loss. With the exception of CCND1, early phase trials have suggested that these genomic alterations could be associated with antitumor activity when targeted with the appropriate compound. Beyond the driver identification at the DNA level, some are developing RNA-based assays to identify pathway activation in individuals. As illustration, gene expression could assess mTOR, CDK4, AR, ER activations. Whether the assessment of pathway activation identifies patients eligible for targeted therapies is not yet proven.The second application of genomics is the identification of genomic alterations involved in drug resistance. As illustration, it has been shown that ESR1 and PTEN mutations could be involved in the resistance to endocrine therapy or PI3K inhibit...
Source: Molecular Cancer Research - Category: Cancer & Oncology Authors: Tags: Keynote Lecture: Oral Presentations - Invited Abstracts Source Type: research